Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GDA | Q9Y2T3 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711471 | 0.82 | CDK2 (0.40) | CDK2GDAPDPK1BRAFDPP4 | |
| SCHEMBL3137199 | 0.79 | DPP4 (0.56) | CDK2GDAPDPK1BRAFCTSS | |
| SCHEMBL1233712 | 0.79 | PDPK1 (0.59) | CDK2GDAPDPK1BRAFDPP4 | |
| SCHEMBL4534389 | 0.79 | CDK2 (0.40) | CDK2GDAPDPK1BRAFCTSS | |
| SCHEMBL2350025 | 0.76 | GDA (0.41) | CDK2GDAPDPK1BRAFDPP4 | |
| Xanthine SCHEMBL4966 | 0.75 | GDA (0.44) | CDK2GDAPDPK1BRAFDPP4 | |
| Xanthine SCHEMBL9443819 | 0.75 | GDA (0.44) | CDK2GDAPDPK1BRAFDPP4 | |
| SCHEMBL4525142 | 0.75 | PDPK1 (0.51) | CDK2PDPK1CTSSCTSK | |
| SCHEMBL3137133 | 0.75 | XDH (0.59) | CDK2BRAFXDHCYP1A2CYP2C19 | |
| SCHEMBL4525061 | 0.75 | CDK2 (0.38) | CDK2GDAPDPK1BRAFCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2010-01-14 | — | — | US | disclosed |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2010-01-07 | — | — | US | disclosed |
| EP-1529049-B1 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARM CORP (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | TEHIM ASHOK | 2008-06-12 | — | — | US | disclosed |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | LIU RUIPING | 2008-05-22 | — | — | US | disclosed |
| US-7342021-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-03-11 | — | — | US | disclosed |
| US-7332486-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. (US) | 2007-04-26 | — | — | US | disclosed |
| EP-1529049-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-05-11 | — | — | EP | disclosed |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | LIU RUIPING (US) | 2004-12-02 | — | — | US | disclosed |
| WO-2004014913-A2 | DERIVATIVES OF 2-TRIFLUORMETHYL-6-AMINOPURINE AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1383767-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2004-01-28 | — | — | EP | disclosed |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2003-03-06 | — | — | US | disclosed |
| WO-2002098878-A1 | TRIFLUOROMETHYLPURINES AS PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093510-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3B, PDE3A | CDK2 853/4885GDA 720/4885PDPK1 538/4885 |
| US-20080139583-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | CDK2 853/4885GDA 720/4885PDPK1 538/4885 |
| US-20030045533-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | CDK2 1035/4885GDA 788/4885PDPK1 320/4885 |
| US-20100004236-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | CDK2 853/4885GDA 720/4885PDPK1 538/4885 |
| US-20040242598-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | CDK2 1035/4885GDA 788/4885PDPK1 320/4885 |
| US-20080119495-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | CDK2 853/4885GDA 720/4885PDPK1 538/4885 |
| US-20100010020-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | CDK2 853/4885GDA 720/4885PDPK1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.